Total Funding
5
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1687942
Regado Biosciences develops antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.
Acquired by 
Tobira Therapeutics
Doug Gooding: PresidentPast Role: Altiris Therapeutics, CEO
David J. Mazzo: CEO
About the Company
Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary
intervention.
It was founded in 2001 and headquartered in Durham, North Carolina.
